| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/31/2013 | WO2013016223A2 Treatments for migraine and related disorders |
| 01/31/2013 | WO2013016148A2 Natriuretic peptide compositions and methods of preparation |
| 01/31/2013 | WO2013016081A1 Notch pathway signaling inhibitor compound |
| 01/31/2013 | WO2013015714A1 Method for treating chronic viral hepatitis c |
| 01/31/2013 | WO2013015674A1 Collagen nanostructures |
| 01/31/2013 | WO2013015611A2 Composition for preventing damage to chondrocytes and regenerating same, including yeast hydrolysate as an active ingredient |
| 01/31/2013 | WO2013015520A1 Novel peptide for increasing vegf expression and pharmaceutical composition including same |
| 01/31/2013 | WO2013015288A1 Lipase activity inhibitor |
| 01/31/2013 | WO2013014687A1 Plantaricins and biomass comprising plantaricins for use in cosmetic and medical fields |
| 01/31/2013 | WO2013014196A1 Aqueous formulation comprising at least a neutral salt and a biopharmaceutical protein |
| 01/31/2013 | WO2013014134A2 Polyoma virus jc peptides and proteins in vaccination and diagnostic applications |
| 01/31/2013 | WO2013014064A1 Product for the parenteral nutrition of obese intensive-care patients |
| 01/31/2013 | WO2013013979A1 Use of citrulline and combination compound for improving male fertility |
| 01/31/2013 | WO2013013799A1 Wound spray |
| 01/31/2013 | WO2013013639A1 Tnf-related apoptosis-inducing ligand fusion protein and preparation and use thereof |
| 01/31/2013 | WO2013013613A1 Use of g-csf dimer in preparation of medicament for treatment of neurodegenerative diseases |
| 01/31/2013 | WO2013013338A1 Use of substances targeting gc-c signaling pathway in diagnosis and treatment for midbrain dopamine neurons diseases |
| 01/31/2013 | WO2013013303A1 Ovarian markers of follicular maturity and uses thereof |
| 01/31/2013 | WO2013013273A1 Modulators of protease activated receptors |
| 01/31/2013 | WO2012172433A3 A sustained -release composition containing a melanocortin receptor ligand as the active ingredient |
| 01/31/2013 | WO2012170899A3 Pharmaceutical compositions containing proteases and methods for the treatment of lysosomal storage diseases |
| 01/31/2013 | WO2012170804A9 Treatments for gastrointestinal disorders |
| 01/31/2013 | WO2012170513A3 He4 based therapy for malignant disease |
| 01/31/2013 | WO2012135630A3 Crk-a novel target for cancer therapy |
| 01/31/2013 | WO2012116210A3 Peptide for the induction of immune tolerance as treatment for systemic lupus erythematosus |
| 01/31/2013 | WO2012094653A4 Compositions and methods for macromolecular drug delivery |
| 01/31/2013 | WO2012037043A9 Treatment of autoimmune inflammation using mir-155 |
| 01/31/2013 | US20130030526 Crosslinked human or animal tissue products and their methods of manufacture and use |
| 01/31/2013 | US20130030359 Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
| 01/31/2013 | US20130030039 Novel multidrug resistance-associated polypeptide |
| 01/31/2013 | US20130030036 Modulation of forkhead box o1a expression |
| 01/31/2013 | US20130029921 Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof |
| 01/31/2013 | US20130029920 Metal Nanoparticles |
| 01/31/2013 | US20130029919 Two part formulation system for opthalmic delivery |
| 01/31/2013 | US20130029918 Methods for reducing vein irritation |
| 01/31/2013 | US20130029917 Use of a peptide hydrolysate of pea as moisturizing active agent |
| 01/31/2013 | US20130029916 Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate |
| 01/31/2013 | US20130029915 Crosslinked human or animal tissue products and their methods of manufacture and use |
| 01/31/2013 | US20130029914 Sebum secretion-blocking composition, and food or beverage containing same |
| 01/31/2013 | US20130029913 Artificial platelets |
| 01/31/2013 | US20130029912 Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis |
| 01/31/2013 | US20130029911 Albumin fusion proteins |
| 01/31/2013 | US20130029910 METHOD OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST |
| 01/31/2013 | US20130029909 Treatment of cancer |
| 01/31/2013 | US20130029908 Cerberus/coco derivatives and uses thereof |
| 01/31/2013 | US20130029907 Novel Polypeptides That Bound to IL-23 Receptor and Inhibit Binding of IL-23 and Cell Signaling Thereof |
| 01/31/2013 | US20130029906 Method of regulating ppar, obesity related pathways and their associated metabolic impact |
| 01/31/2013 | US20130029905 Formulation containing curcuminoids exhibiting enhanced bioavailability |
| 01/31/2013 | US20130029904 Hcv combination therapy |
| 01/31/2013 | US20130029903 Azuvirin Peptides |
| 01/31/2013 | US20130029902 Cxc chemokine receptor 4 (cxcr4) antagonistic polypeptide |
| 01/31/2013 | US20130029901 Methods and compounds for the targeted delivery of agents to bone for interaction therewith |
| 01/31/2013 | US20130029900 Novel maytansinoid derivatives with peptide linker and conjugates thereof |
| 01/31/2013 | US20130029425 Genetic Inhibition by Double-Stranded RNA |
| 01/31/2013 | US20130028984 Natural tissue scaffolds as tissue fillers |
| 01/31/2013 | US20130028978 Compositions and methods for wound treatment |
| 01/31/2013 | US20130028963 Forming an Artificial Cell with controlled membrane composition, asymmetry, and contents |
| 01/31/2013 | US20130028962 Triggered Cargo Release from Nanoparticle Stabilized Liposomes |
| 01/31/2013 | US20130028959 Liposomes for Preventing the Spread of HIV |
| 01/31/2013 | US20130028956 Method for preventing or treating memory impairment and pharmaceutical compositions useful therefore |
| 01/31/2013 | US20130028954 Hemostatic dressing |
| 01/31/2013 | US20130028940 Caspofungin formulations |
| 01/31/2013 | US20130028939 Chimeric human beta defensins |
| 01/31/2013 | US20130028930 Albumin Derivatives and Variants |
| 01/31/2013 | US20130028912 Tweak/fn14 system regulates skeletal muscle atrophy and regeneration |
| 01/31/2013 | US20130028911 Vascular endothelial cell growth factor antagonists |
| 01/31/2013 | US20130028910 Hmg1 antibody for treating inflammatory conditions |
| 01/31/2013 | US20130028902 Osteocalcin as a treatment for male reproductive disorders |
| 01/31/2013 | US20130028901 Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| 01/31/2013 | US20130028896 Semaphorin 3C (Sema3C) Inhibitor Therapeutics, Methods, and Uses |
| 01/31/2013 | US20130028895 Exosome inhibiting agents and uses thereof |
| 01/31/2013 | US20130028894 Methods of treating il-tif associated inflammatory or immune diseases using antibodies against soluble zcytor 11 cytokine receptors |
| 01/31/2013 | US20130028886 Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and tumor initiating cells |
| 01/31/2013 | US20130028885 Methods to predict and prevent resistance to taxoid compounds |
| 01/31/2013 | US20130028884 Composition and method for treatment of bruising |
| 01/31/2013 | US20130028883 Treatment of ischemic episodes and cerebroprotection through Misoprostol |
| 01/31/2013 | US20130028882 Antiviral compositions and methods of their use |
| 01/31/2013 | US20130028881 Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies |
| 01/31/2013 | US20130028880 Apyrase therapy for bleeding conditions |
| 01/31/2013 | US20130028869 Feed supplement comprising oligosaccharides and medium chain fatty acids |
| 01/31/2013 | US20130028867 Long-acting interferon beta formulation using immunoglobulin fragment |
| 01/31/2013 | US20130028866 Treatment of multiple sclerosis with combination of laquinimod and interferon-beta |
| 01/31/2013 | US20130028865 Combination of a Macrocyclic Inhibitor of HCV, A Non-Nucleoside and a Nucleoside |
| 01/31/2013 | US20130028864 Anti-inflammatory compositions for treating brain inflammation |
| 01/31/2013 | US20130028863 Promyelocytic leukemia protein as a redox sensor |
| 01/31/2013 | US20130028862 Treatment with anti-vegf antibodies |
| 01/31/2013 | US20130028861 Cytokines for the treatment of addictions |
| 01/31/2013 | US20130028860 Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue and/or fever |
| 01/31/2013 | US20130028859 Hepatitis C Virus Inhibitors |
| 01/31/2013 | US20130028856 Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions |
| 01/31/2013 | US20130028854 Osmoprotective Complexes for Prevention of Mitochondrial Free Radical Damage Related Skin Aging |
| 01/31/2013 | CA2843611A1 Compositions and methods for reducing the incidence of equine digestive disorders |
| 01/31/2013 | CA2843014A1 Use of il-12 to generate endogenous erythropoietin |
| 01/31/2013 | CA2842969A1 Use of g-csf dimer in preparation of medicament for treatment of neurodegenerative diseases |
| 01/31/2013 | CA2842839A1 Ovarian markers of follicular maturity and uses thereof |
| 01/31/2013 | CA2842796A1 Tumor selective chemokine modulation |
| 01/31/2013 | CA2842543A1 Polyoma virus jc peptides and proteins in vaccination and diagnostic applications |
| 01/31/2013 | CA2842487A1 Wound spray |
| 01/31/2013 | CA2841541A1 Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (cftr) gene |
| 01/31/2013 | CA2841178A1 Notch pathway signaling inhibitor compound |